MediWound's EscharEx Shows Safe, Effective, Rapid Debridement Of Leg Ulcers
February 2, 2024
CNBC
MediWound Ltd (NASDAQ: MDWD ) announced results from its Phase 2 pharmacology study of EscharEx for the debridement of lower leg ulcers.
70% of patients achieved complete debridement during treatment within up to 8 applications. On average, complete debridement was achieved after 3.9 applications of EscharEx.
Additionally, ... Full story available on Benzinga.com
SweepCast
Simplest Unusual Options Activity Platform for traders. SweepCast can be used for swing or day traders who are looking to get insights on where Smart money is flowing, sign up today.